Characteristic
|
Study population
|
T2DM
|
COPD
| |
RA
| |
HT
| |
---|
Cases
|
Controls
|
Cases
|
Controls
|
Cases
|
Controls
|
Cases
|
Controls
|
Cases
|
Controls
|
---|
n = 604
|
n = 604
|
n = 151
|
n = 151
|
n = 151
|
n = 151
|
n = 151
|
n = 151
|
n = 151
|
n = 151
|
---|
Age, mean ± SD (years)
|
54.9 ± 13.9
|
47.1 ± 15.5a
|
52.2 ± 12.8
|
46.6 ± 15.7a
|
60.3 ± 14.2
|
53.1 ± 16.7a
|
50.1 ± 13.4
|
41.6 ± 15.3a
|
56.8 ± 13.1
|
47 ± 12.1a
|
Age group, n (%)
|
< 50 years
|
216 (35.8)
|
320 (53.0)a
|
68 (45.0)
|
83 (55.0)
|
31 (20.5)
|
57 (37.7)a
|
71 (47.0)
|
103 (68.2)a
|
46 (30.5)
|
77 (51.0)a
|
> 50 years
|
388 (64.2)
|
284 (47.0)
|
83 (55.0)
|
68 (45.0)
|
120 (79.5)
|
94 (62.3)
|
80 (53.0)
|
48 (31.8)
|
105 (69.5)
|
74 (49.0)
|
Sex, n (%)
|
Female
|
377 (62.4)
|
394 (65.2)
|
101 (66.9)
|
95 (62.9)
|
69 (45.7)
|
92 (60.9)b
|
126 (83.4)
|
110 (72.8)b
|
81 (53.6)
|
97 (64.2)
|
Male
|
227 (37.6)
|
210 (34.8)
|
50 (33.1)
|
56 (37.1)
|
82 (54.3)
|
59 (39.1)
|
25 (16.6)
|
41 (27.2)
|
70 (46.4)
|
54 (35.8)
|
Years of education, n (%)
|
< 9 years
|
363 (60.1)
|
341 (56.5)
|
90 (59.6)
|
82 (54.3)
|
89 (58.9)
|
76 (50.3)
|
90 (59.6)
|
85 (56.3)
|
94 (62.3)
|
98 (64.9)
|
> 9 years
|
241 (39.9)
|
263 (43.5)
|
61 (40.4)
|
69 (45.7)
|
62 (41.1)
|
75 (49.7)
|
61 (40.4)
|
66 (43.7)
|
57 (37.7)
|
53 (35.1)
|
Health care, n (%)
|
Yes
|
476 (78.8)
|
453 (75)
|
122 (80.8)
|
118 (78.1)
|
116 (76.8)
|
121 (80.1)
|
112 (74.2)
|
116 (76.8)
|
126 (83.4)
|
98 (64.9)a
|
No
|
128 (21.2)
|
151 (25)
|
29 (19.2)
|
33 (21.9)
|
35 (23.2)
|
30 (19.9)
|
39 (25.8)
|
35 (23.2)
|
25 (16.6)
|
53 (35.1)
|
Previous clinical trial participation (case group only), n (%)
|
One
|
395 (65.4)
| |
89 (58.9)
| |
89 (58.9)
| |
119 (78.8)
| |
98 (64.9)
| |
Two to three
|
196 (32.5)
| |
60 (39.7)
| |
56 (37.1)
| |
28 (18.5)
| |
52 (34.4)
| |
Three to six
|
10 (1.7)
| |
2 (1.3)
| |
5 (3.3)
| |
2 (1.3)
| |
1 (0.7)
| |
More than six
|
3 (0.5)
| |
0 (0)
| |
1 (0.7)
| |
2 (1.3)
| |
0 (0)
| |
- aP ≤ 0.001; bP ≤ 0.05
- T2DM Type 2 diabetes mellitus, COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis, HT hypertension